BRIEF published on 11/24/2025 at 06:35, 10 months 1 day ago Formycon s'associe à NTC pour la commercialisation de biosimilaires en Italie Formycon AG Ophtalmologie FYB203/Baiama® Partenariats En Matière De Biosimilaires Marché Pharmaceutique Italien
BRIEF published on 11/24/2025 at 06:35, 10 months 1 day ago Formycon Partners with NTC for Biosimilar Commercialization in Italy Formycon AG Ophthalmology Biosimilar Partnerships Italy Pharmaceutical Market FYB203/Baiama®
PRESS RELEASE published on 11/24/2025 at 06:30, 10 months 1 day ago NTC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/Baiama® in Italy Formycon AG partners with NTC for Eylea biosimilar commercialization in Italy. Agreement includes royalties and supply chain organization Italy Formycon AG Commercialization Eylea Biosimilar NTC
BRIEF published on 11/20/2025 at 17:05, 10 months 4 days ago First Berlin Reaffirms Buy Rating for Formycon AG BUY Rating Formycon AG Revenue Guidance Dupixent Keytruda Biosimilar
BRIEF published on 11/20/2025 at 17:05, 10 months 4 days ago First Berlin réaffirme sa recommandation d'achat sur Formycon AG Formycon AG Dupixent Évaluation D'achat Prévisions De Recettes Biosimilaire De Keytruda
PRESS RELEASE published on 11/20/2025 at 17:00, 10 months 4 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Buy recommendation on Formycon AG (DE000A1EWVY8) to EUR 53 target price post Q3 results surpassing expectations and upcoming FYB206 study endpoint results First Berlin Equity Research Buy Recommendation Formycon AG FYB206 EUR 53 Target Price
BRIEF published on 11/20/2025 at 06:35, 10 months 5 days ago Ranibizumab Biosimilar Epruvy® Launched in Germany Formycon AG Ranibizumab Biosimilar Germany Launch Ophthalmic Care
BRIEF published on 11/20/2025 at 06:35, 10 months 5 days ago Lancement en Allemagne du biosimilaire de ranibizumab Epruvy® Formycon AG Ranibizumab Biosimilaire Lancement En Allemagne Soins Ophtalmiques
PRESS RELEASE published on 11/20/2025 at 06:30, 10 months 5 days ago Ranibizumab Biosimilar Epruvy® launched in Germany Ranibizumab Biosimilar Epruvy® launched in Germany by Formycon AG, Bioeq AG, and Sandoz AG under license agreement, expanding patient access to treatment options for nAMD and retinopathies Formycon AG Germany Ranibizumab Sandoz AG Epruvy
BRIEF published on 11/17/2025 at 06:35, 10 months 8 days ago Formycon franchit une étape importante avec FYB208 pour Dupixent® Maladies Inflammatoires Chroniques Formycon Biosimilaires Dupilumab Preuve Technique De Similitude
Published on 09/25/2026 at 00:30, 6 hours 15 minutes ago Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Published on 09/25/2026 at 00:15, 6 hours 30 minutes ago CoTec Holdings Corp. Announces Extension of Private Placement of Unsecured Convertible Debentures
Published on 09/24/2026 at 22:01, 8 hours 44 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 15 hours 50 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/25/2026 at 06:30, 15 minutes ago Schindler Holding Ltd.: Changes to the Group Executive Committee
Published on 09/25/2026 at 02:45, 4 hours ago Huagui Group: un acteur mondial sur deux marchés aquatiques de plus de 100 milliards de RMB, tandis que la racine de lotus de Honghu se classe au premier rang pour sa teneur en antioxydants
Published on 09/25/2026 at 02:45, 4 hours ago Huagui Group: A Global Player Across Two RMB100-Billion Aquatic Markets, as Honghu Lotus Root Ranks No. 1 in Antioxidant Content
Published on 09/24/2026 at 20:29, 10 hours 16 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 11 hours 45 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:31, 12 hours 14 minutes ago LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:00, 12 hours 45 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 12 hours 45 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
